Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Proc Natl Acad Sci U S A ; 113(17): 4853-8, 2016 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-27071089

RESUMO

Lysergic acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the human brain have never been studied before with modern neuroimaging. Here, three complementary neuroimaging techniques: arterial spin labeling (ASL), blood oxygen level-dependent (BOLD) measures, and magnetoencephalography (MEG), implemented during resting state conditions, revealed marked changes in brain activity after LSD that correlated strongly with its characteristic psychological effects. Increased visual cortex cerebral blood flow (CBF), decreased visual cortex alpha power, and a greatly expanded primary visual cortex (V1) functional connectivity profile correlated strongly with ratings of visual hallucinations, implying that intrinsic brain activity exerts greater influence on visual processing in the psychedelic state, thereby defining its hallucinatory quality. LSD's marked effects on the visual cortex did not significantly correlate with the drug's other characteristic effects on consciousness, however. Rather, decreased connectivity between the parahippocampus and retrosplenial cortex (RSC) correlated strongly with ratings of "ego-dissolution" and "altered meaning," implying the importance of this particular circuit for the maintenance of "self" or "ego" and its processing of "meaning." Strong relationships were also found between the different imaging metrics, enabling firmer inferences to be made about their functional significance. This uniquely comprehensive examination of the LSD state represents an important advance in scientific research with psychedelic drugs at a time of growing interest in their scientific and therapeutic value. The present results contribute important new insights into the characteristic hallucinatory and consciousness-altering properties of psychedelics that inform on how they can model certain pathological states and potentially treat others.


Assuntos
Mapeamento Encefálico/métodos , Encéfalo/efeitos dos fármacos , Estado de Consciência/efeitos dos fármacos , Alucinações/fisiopatologia , Alucinógenos/farmacologia , Dietilamida do Ácido Lisérgico/farmacologia , Imageamento por Ressonância Magnética/métodos , Magnetoencefalografia/métodos , Imagem Multimodal/métodos , Encéfalo/fisiopatologia , Circulação Cerebrovascular/efeitos dos fármacos , Conectoma , Estado de Consciência/fisiologia , Alucinações/induzido quimicamente , Humanos , Rede Nervosa/efeitos dos fármacos , Oxigênio/sangue , Receptor 5-HT2A de Serotonina/fisiologia , Agonistas do Receptor 5-HT2 de Serotonina/farmacologia , Marcadores de Spin , Transmissão Sináptica/efeitos dos fármacos
2.
Psychopharmacology (Berl) ; 237(12): 3803, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33089876

RESUMO

The manufacturer of the drug product was Onyx Scientific Limited UK, to cGMP standards.

3.
Psychopharmacology (Berl) ; 237(3): 841-853, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31853557

RESUMO

Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT2A receptor signaling, supporting their evaluation as a therapeutic for neuroinflammation associated with neurodegenerative disease. OBJECTIVE: This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally repeated administration of 5 µg, 10 µg, and 20 µg LSD in older healthy individuals. In the current paper, we present safety, tolerability, pharmacokinetics, and pharmacodynamic measures that relate to safety, tolerability, and dose response. METHODS: This was a phase 1 double-blind, placebo-controlled, randomized study. Volunteers were randomly assigned to 1 of 4 dose groups (5 µg, 10 µg, 20 µg LSD, and placebo), and received their assigned dose on six occasions (i.e., every 4 days). RESULTS: Forty-eight older healthy volunteers (mean age = 62.9 years) received placebo (n = 12), 5 µg (n = 12), 10 µg (n = 12), or 20 µg (n = 12) LSD. LSD plasma levels were undetectable for the 5 µg group and peak blood plasma levels for the 10 µg and 20 µg groups occurred at 30 min. LSD was well tolerated, and the frequency of adverse events was no higher than for placebo. Assessments of cognition, balance, and proprioception revealed no impairment. CONCLUSIONS: Our results suggest safety and tolerability of orally administered 5 µg, 10 µg, and 20 µg LSD every fourth day over a 21-day period and support further clinical development of LSD for the treatment and prevention of Alzheimer's disease (AD).


Assuntos
Cognição/efeitos dos fármacos , Alucinógenos/administração & dosagem , Alucinógenos/farmacologia , Dietilamida do Ácido Lisérgico/administração & dosagem , Dietilamida do Ácido Lisérgico/farmacocinética , Propriocepção/efeitos dos fármacos , Administração Oral , Idoso , Cognição/fisiologia , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Propriocepção/fisiologia , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia
4.
Psychopharmacology (Berl) ; 236(4): 1159-1170, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30478716

RESUMO

RATIONALE: Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neurochemical effects on interval timing from indirect effects attributable to altered states of consciousness. METHODS: We conducted a randomised, double-blind, placebo-controlled study contrasting oral administration of placebo with three microdoses of LSD (5, 10, and 20 µg) in older adults. Subjective drug effects were regularly recorded and interval timing was assessed using a temporal reproduction task spanning subsecond and suprasecond intervals. RESULTS: LSD conditions were not associated with any robust changes in self-report indices of perception, mentation, or concentration. LSD reliably produced over-reproduction of temporal intervals of 2000 ms and longer with these effects most pronounced in the 10 µg dose condition. Hierarchical regression analyses indicated that LSD-mediated over-reproduction was independent of marginal differences in self-reported drug effects across conditions. CONCLUSIONS: These results suggest that microdose LSD produces temporal dilation of suprasecond intervals in the absence of subjective alterations of consciousness.


Assuntos
Estado de Consciência/efeitos dos fármacos , Alucinógenos/administração & dosagem , Dietilamida do Ácido Lisérgico/administração & dosagem , Percepção do Tempo/efeitos dos fármacos , Idoso , Estado de Consciência/fisiologia , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Percepção do Tempo/fisiologia
5.
Sci Rep ; 9(1): 16324, 2019 11 19.
Artigo em Inglês | MEDLINE | ID: mdl-31745107

RESUMO

Studying transitions in and out of the altered state of consciousness caused by intravenous (IV) N,N-Dimethyltryptamine (DMT - a fast-acting tryptamine psychedelic) offers a safe and powerful means of advancing knowledge on the neurobiology of conscious states. Here we sought to investigate the effects of IV DMT on the power spectrum and signal diversity of human brain activity (6 female, 7 male) recorded via multivariate EEG, and plot relationships between subjective experience, brain activity and drug plasma concentrations across time. Compared with placebo, DMT markedly reduced oscillatory power in the alpha and beta bands and robustly increased spontaneous signal diversity. Time-referenced and neurophenomenological analyses revealed close relationships between changes in various aspects of subjective experience and changes in brain activity. Importantly, the emergence of oscillatory activity within the delta and theta frequency bands was found to correlate with the peak of the experience - particularly its eyes-closed visual component. These findings highlight marked changes in oscillatory activity and signal diversity with DMT that parallel broad and specific components of the subjective experience, thus advancing our understanding of the neurobiological underpinnings of immersive states of consciousness.


Assuntos
Encéfalo/fisiologia , Estado de Consciência/efeitos dos fármacos , Alucinógenos/administração & dosagem , N,N-Dimetiltriptamina/administração & dosagem , Administração Intravenosa , Adulto , Encéfalo/efeitos dos fármacos , Estudos de Casos e Controles , Estado de Consciência/fisiologia , Eletroencefalografia , Feminino , Alucinógenos/sangue , Alucinógenos/farmacologia , Humanos , Masculino , Análise Multivariada , N,N-Dimetiltriptamina/sangue , N,N-Dimetiltriptamina/farmacologia
6.
Biol Psychiatry ; 78(8): 554-62, 2015 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-24495461

RESUMO

BACKGROUND: The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals. METHODS: In a double-blind, placebo-controlled, balanced-order study, MDMA was orally administered to 25 physically and mentally healthy individuals. Arterial spin labeling and seed-based resting state functional connectivity (RSFC) were used to produce spatial maps displaying changes in cerebral blood flow (CBF) and RSFC after MDMA administration. Participants underwent two arterial spin labeling and two blood oxygen level-dependent scans in a 90-minute scan session; MDMA and placebo study days were separated by 1 week. RESULTS: Marked increases in positive mood were produced by MDMA. Decreased CBF only was observed after MDMA, and this was localized to the right medial temporal lobe (MTL), thalamus, inferior visual cortex, and the somatosensory cortex. Decreased CBF in the right amygdala and hippocampus correlated with ratings of the intensity of global subjective effects of MDMA. The RSFC results complemented the CBF results, with decreases in RSFC between midline cortical regions, the medial prefrontal cortex, and MTL regions, and increases between the amygdala and hippocampus. There were trend-level correlations between these effects and ratings of intense and positive subjective effects. CONCLUSIONS: The MTLs appear to be specifically implicated in the mechanism of action of MDMA, but further work is required to elucidate how the drug's characteristic subjective effects arise from its modulation of spontaneous brain activity.


Assuntos
Afeto/fisiologia , Tonsila do Cerebelo/efeitos dos fármacos , N-Metil-3,4-Metilenodioxianfetamina/administração & dosagem , Oxigênio/sangue , Serotoninérgicos/administração & dosagem , Adulto , Circulação Cerebrovascular/efeitos dos fármacos , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Hipocampo/efeitos dos fármacos , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Córtex Pré-Frontal/efeitos dos fármacos , Lobo Temporal/efeitos dos fármacos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA